Status:
RECRUITING
99mTc-H7ND SPECT/CT Imaging in NSCLC
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
NSCLC
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
To study the clinical application of 99mTc-H7ND SPECT/CT imaging in the efficacy evaluation and prediction of non-small cell lung cancer (NSCLC)
Detailed Description
This study was a prospective, controlled, single-center clinical study. To evaluate the value of 99mTc-H7ND imaging in the evaluation of stable disease in patients with non-small cell lung cancer (NS...
Eligibility Criteria
Inclusion
- Patients aged from 18 to 80 years old;
- patients with NSCLC confirmed by needle aspiration cytology or surgical pathology, who cannot undergo radical surgery due to recurrence, metastasis or patient's own conditions;
- Has completed 2-4 cycles of first-line therapy (including chemotherapy, immunotherapy, chemotherapy combined with immunotherapy, chemotherapy combined with targeted therapy, etc.), and has SD assessed by RECIST 1.1 during the same period;
- Patients had at least one measurable lesion;
- No local radiotherapy for primary or metastatic lesions within 28 days;
- ECOG score 0-2;
- Expected survival time ≥3 months;
- Voluntarily participate and sign informed consent.
Exclusion
- Women who plan to become pregnant within 6 months, or are pregnant or lactating.
- Patients with severe brain or bone metastases;
- Severe anemia and severe liver and kidney damage;
- Pathological or long-term follow-up results may not be available;
- The relevant control imaging data and clinical data were not available;
- Severe illness is difficult to cooperate (such as acute cardiovascular and cerebrovascular events or serious cardiovascular diseases);
- Received any surgery or invasive treatment or procedure within 4 weeks before enrollment;
- Cannot tolerate standard second-line therapy or other first-line therapies.
- Known allergy to 99mTc-H7ND or any of its components; He had a history of severe allergies;
- Protocol imaging contraindications were present;
- The investigator considered it inappropriate to participate in the study.
Key Trial Info
Start Date :
September 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 10 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05999214
Start Date
September 13 2023
End Date
August 10 2026
Last Update
September 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China, 710061